Skip to content skip to primary navi skip to secondary navi skip to meta navi search

Publikationen 2010

Originalarbeiten

  • Herbst C, Rehan FA, Brillant C, Bohlius J, Skoetz N, Schulz H, Monsef I, Specht L, Engert A. Combined modality treatment improves tumour control and overall survival in patients with early stage Hodgkin lymphoma: a systematic review. Haematologica 95:494-500 (2010)
  • Böll B, Eichenauer D, von Tresckow B, Peine D, Hallek M, Engert A,  Hübel K. Activity of Cetuximab as single agent in a patient with relapsed Multiple Myeloma. Letter to the editor. Leukemia & Lymphoma 51(3):562-64 (2010)
  • Juergens A, Pels H, Rogowski S, Fliessbach K, Glasmacher A, Engert A, Reiser M, Diehl V, Vogt-Schaden M, Egerer G, Schackert G, Reichmann H, Kroschinsky F, Bode U, Herrlinger U, Linnebank M, Deckert M, Fimmers R, Schmidt-Wolf I, Schlegel U. Long-term survival with favourable cognitive outcome after chemotherapy in primary central nervous systems lymphoma. Ann Neurol 67:182-89 (2010)
  • Pels H, Jürgens A, Schirgens I, Glasmacher A, Schulz H, Engert Am, Schackert G, Reichmann H, Kroschinsky F, Vogt-Schaden M, Egerer G, Bode U, Deckert M, Fimmers R, Urbach H, Schmidt-Wolf I, Schlegel U. Early complete response during chemotherapy redicts favorable outcome in patients with primary CNS lymphoma. Neuro-Oncology 12(7):720-24 (2010)
  • Dietlein M, Börner SM, Fischer T, Hansen H, Schnell R, Zimmermanns B, Tawadros S, Engert A, Staak O, Pogge von Strandmann E, Kobe C, Schicha H, Schomäcker K. Development of anti-CD30 radioimmunoconstructs (RICs) for treatment of Hodgkin’s lymphoma. Nuklearmedizin Feb 2;49(3):97-105 (2010)
  • Behringer K, Wildt L, Mueller H, Mattle V, Ganitis P, van den Hoonard B, Ott HW, Hofer S, Plütschow A, Diehl V, Engert A. No protection of the ovarian follicle pool with the use of GnRH-analogues or oral contraceptives in young women treated with escalated BEACOPP for advanced-stage Hodgkin Lymphoma (HL). Final results of a phase II trial from the German Hodgkin Study Group (GHSG). Ann Oncol 21:2052-60 (2010)
  • Engert A, Josting A, Haverkamp H, Villalobos M, Lohri A, Soekler M, Zijlstra J, Sturm I, Topp M, Rank A, Zenz T, Vogelhuber M, Nogova L, Borchmann P, Fuchs M, Flechtner HH, Diehl V. Epoetin alfa in patients with advanced-stage Hodgkin lymphoma: Results of the randomized placebo controlled GHSG HD15EPO trial. J Clin Oncol May 1;28(13):2239-45 (2010)
  • Halbsguth TV, Nogova L, Mueller H, Sieniawski M, Eichenauer DA, Schober T, Nisters-Backes H, Borchmann P, Engert A, Josting A. Phase II study of BACOPP (Bleomycin, Adriamycin, Cyclophosphamide, Vincristine, Procarbazine and Prednisone) in older patients with Hodgkin lymphoma: A report from the German Hodgkin Study Group (GHSG). Blood Sep 23;116(12):2026-32 (2010)
  • Engert A, Eichenauer D, Dreyling M. Hodgkin Lymphoma - ESMO clinical recommendiations for diagnosis, treatment and follow-up. ESMO Guidelines. Ann Oncol, 21(Suppl.5):v168-v171 (2010)
  • Engert A, Plütschow A, Eich HT, Lohri A, Dörken B, Borchmann P, Berger B, Greil R, Wilborn KC, Wilhelm M, Debus J, Eble MJ, Sökler M, Ho A, Rank A, Ganser A, Trümper L, Bokemeyer C, Kirchner H, Schubert J, Král Z, Fuchs M, Müller-Hermelink HK, Müller RP, Diehl V. Reduced treatment intensity in patients with early stage Hodgkin Lymphoma. New Engl J Med 363(7):640-52 (2010)
  • Eich HT, Diehl V, Görgen H, Lohri A, Markova J, Debus J, Ho A, Dörken B, Rank A, Grosu AL, Wiegel T, Karstens JH, Greil R, Willich N, Schmidberger H, Döhner H, Borchmann P, Müller-Hermelink HK, Müller RP, Engert A. Intensified chemotherapy and dose-reduced involved field radiotherapy in patients with early unfavorable Hodgkin lymphoma: final analysis of the German Hodgkin Study Group (GHSG) HD11 trial. J Clin Oncol J Clin Oncol Sep 20;28(27):4199-206 (2010)
  • Josting A, Müller H, Borchmann P, Baars JW, Metzner B, Döhner H, Aurer I, Smardova L,  Fischer T, Niederwieser D, Schäfer-Eckart K, Schmitz N, Sureda A, Glossmann J, Diehl V, DeJong D, Hansmann M, Raemaekers J, Engert A. Dose intensity of chemotherapy in patients with relapsed Hodgkin lymphoma. J Clin Oncol Dec 1;28(34):5074-80 (2010)
  • Enciso-Mora V, Broderick P, Ma Y, Jarrett RF, Hjalgrim H, Hemminki K, van den Berg A, Olver B, Lloyd A, Lightfoot T, van Leeuwen FE, Försti A, Diepstra A, Broeks A, Vijayakrishnan J, Shield L, Lake A, Montgomery D, Roman E, Engert A, Pogge von Strandmann E, Reiners K,  Nolte I, Smedby KE, Adami HO, Russell NS, Glimelius B, Hamilton-Dutoit S, de Bruin M, Ryder LP, Molin D, Sorensen KM, Chang ET, Taylor M, Cooke R, Hofstra R, Westers H, van Wezel T, van Eijk R, Ashworth A, Rostgaard K, Melbye M, Swerdlow AJ, Houlston RS. A genome-wide association study of Hodgkin Lymphoma identifies new susceptibility loci at 2p16.1 (REL), 8q24.21 and 10p14 (GATA3). Nature Genetics Dec 10;42(12):1126-30 (2010)
  • Böll B, Borchmann P, Topp MS, Hänel M, Reiners KS, Engert A, Naumann R. Lenalidomid in patients with refractory or multiple relapsed Hodgkin lymphoma. Br J Haematol 148(3):480-2 (2010)

Übersichtsarbeiten

  • Böll B, Engert A, Borchmann P. Experimentelle Therapie des Hodgkin Lymphoms. Themenheft „Morbus Hodgkin“. Der Onkologe 16:48-54 (2010)
  • Engert A. Aktuelle Therapiestrategien der Deutschen Hodgkin Studiengruppe (GHSG). Themenheft „Morbus Hodgkin“. Der Onkologe 16:28-34 (2010)
  • Kriz J, Müller RP, Engert A, Eich T. Lymphozytenprädominantes Hodgkin Lymphom. Themenheft „Morbus Hodgkin“. Der Onkologe 16:41-47 (2010)
  • Dietlein M, Eich HT, Fuchs M, Borchmann P, Engert A, Kobe C. PET beim Hodgkin Lymphom – Verbessert die Positronen-Emissions-Tomographie die Behandlung? Themenheft „Morbus Hodgkin“. Der Onkologe 16:18-27 (2010)
  • Gawlik B, Engert A. Hodgkin Lymphom. Aktuelle Therapiestandards und neue Behandlungskonzepte. Best Practice Onkologie Vol 5, No 2, April (2010) [Epub ahead of print]
  • Armitage JO, Diehl V, Engert A (GHSG), Jacobs P, Wood L (Groote Schuur Hospitals Teaching Group). Proceedings of the 13th biennial South African Lymphoma Study Group Meeting –Cape Town, Oct 2008. Transfus Apher Sci Apr 42(2):125-8 (2010)
  • Bauer K, Herbst C, Brillant C, Monsef I, Kluge S, Skoetz N, Engert A. Eleventh biannual report of the Cochrane Haematological Malignancies Group: Focus on Hodgkin lymphoma. J Natl Cancer Inst. Jun 16;102(12):E1 (2010)
  • Kobe C, Dietlein M, Kriz J, Furth C, Fuchs M, Borchmann P, Engert A, Eich HT. The role of PET in Hodgkin’s lymphoma and its impact on radiation oncology. Expert Rev Anticancer Ther 10(9): 1419-1428 (2010)
  • Engert A. Therapie des Hodgkin Lymphoms in frühen Stadien. Themenheft “Morbus Hodgkin”. Krebsmedizin Heft 3:123-129 (2010)
  • Von Tresckow B, Engert A. Fortgeschrittene Stadien und Rezidive des Hodgkin Lymphoms. Themenheft “Morbus Hodgkin”. Krebsmedizin Heft 3:130-136 (2010)
  • Kobe C, Dietlein M, Fuchs M. Intepretation and validation of interim positron emission tomography in Hodgkin lymphoma. Leuk Lymphoma 51(3):552-3 (2010)
  • Borchmann P, Engert A. The past: what we have learned in the last decade. Hematology Am Soc Hematol Educ Program:101-7 (2010)
  • Engert A, Eichenauer DA, Dreyling M. ESMO Guidelines Working Group. Hodgkins lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 21;Suppl 5:v168-71 (2010)
  • Siebert R, Brück W, Engert A, Finke J, Illerhaus G, Klapper W, Korfel A, Küppers R, Maarouf M, Paulus W, Schlegel U. Fachübergreifende Expertise. Netzwerk Lymphome und Lymphomatoide Läsionen (NLLLN). Dt. Ärzteblatt 107(4)29. Jan:131 (2010)